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Abstract: The 5-Hydroxymethylcytosine (5-hmC) is an epigenetic
modification whose role in the pathogenesis of metabolic-related com-
plex diseases remains unexplored; 5-hmC appears to be prevalent in the
mitochondrial genome. The Ten-Eleven-Translocation (TET) family of
proteins is responsible for catalyzing the conversion of 5-methylcyto-
sine to 5-hmC. We hypothesized that epigenetic editing by 5-hmC might
be a novel mechanism through which nonalcoholic fatty liver disease
(NAFLD)-associated molecular traits could be explained.
Hence, we performed an observational study to explore global levels
of 5-hmC in fresh liver samples of patients with NAFLD and controls
(n¼ 90) using an enzyme-linked-immunosorbent serologic assay and
immunohistochemistry. We also screened for genetic variation in TET
1–3 loci by next generation sequencing to explore its contribution to the
disease biology. The study was conducted in 2 stages (discovery and
replication) and included 476 participants.
We observed that the amount of 5-hmC in the liver of both NAFLD
patients and controls was relatively low (up to 0.1%); a significant
association was found with liver mitochondrial DNA copy number
(R¼ 0.50, P¼ 0.000382) and PPARGC1A-mRNA levels (R¼0.57,
P¼ 0.04).
We did not observe any significant difference in the 5-hmC nuclear
immunostaining score between NAFLD patients and controls; never-
theless, we found that patients with NAFLD (0.4 0.5) had significantly
lower nonnuclear-5-hmC staining compared with controls (1.8 0.8),
means standard deviation, P¼ 0.028. The missense p.Ile1123Met
variant (TET1-rs3998860) was significantly associated with serum
levels of caspase-generated CK-18 fragment-cell death biomarker in
the discovery and replication stage, and the disease severity (odds ratio:
1.47, 95% confidence interval: 1.10–1.97; P¼ 0.005). The p.Ile1762-
Val substitution (TET2-rs2454206) was associated with liver
PPARGC1A-methylation and transcriptional levels, and Type 2
diabetes.
Our results suggest that 5-hmC might be involved in the pathogen-
esis of NAFLD by regulating liver mitochondrial biogenesis and
PPARGC1A expression. Genetic diversity at TET loci suggests an
‘‘epigenetic’’ regulation of programmed liver-cell death and a TET-
mediated fine-tuning of the liver PPARGC1A-transcriptional program.
(Medicine 94(36):e1480)
Abbreviations: 5-hmC = 5-hydroxymethylcytosine, CK-18 =
caspase-generated CK-18 fragment, mtDNA = mitochondrial
DNA, NAFLD = nonalcoholic fatty liver disease, nDNA =
nuclear DNA, NGS = next generation sequencing, NNLH =
near-normal liver histology, PPARGC1A = peroxisome
proliferator-activated receptor gamma coactivator 1a, TET =
Ten-Eleven-Translocation.
INTRODUCTION
N onalcoholic fatty liver disease (NAFLD) is a highlyprevalent chronic liver disease1 that is clustered in the
metabolic syndrome (MetS) along with other cardiometabolic
comorbidities.2–4 In fact, NAFLD is not only a component of
the diagnostic criteria for MetS but is critically involved in the
development of insulin resistance.5,6
The clinical picture of NAFLD might present in a rela-
tively mild form, characterized by abnormal hepatic triglyceride
accumulation, named simple or bland steatosis or nonalcoholic
fatty liver (NAFL). However, it might progress to a more severe
clinical condition, named nonalcoholic steatohepatitis (NASH),
which is characterized by fat accumulation accompanied by
liver cell injury, a mixed inflammatory lobular infiltrate, and
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variable fibrosis.7,8 Notably, NAFL is not necessarily associated
with a benign prognosis.9 A recent meta-analysis showed that
patients with NAFL could develop liver fibrosis over time.10 In
addition, NAFL may seriously increase the probability of
exacerbating associated co-morbidities, including cardiovascular
disease.11
Like many other complex diseases, NAFLD is under both
genetic and environmental influences.12 Recent evidence from
human studies indicates presence of tissue-specific epigenetic
modifications in both nuclear6,13,14 and mitochondrial (mt)
genome.15 These are involved not only in NAFLD pathogenesis
and histological disease progression but are relevant to
the pathophysiology of the MetS-associated phenotypes.6,15
Furthermore, there is compelling evidence showing that mito-
chondrial function,15–19 and mitochondrial DNA (mtDNA) copy
number are both diminished in NAFLD.6 Notably, the afore-
mentioned molecular changes are not only determinants of the
disease prognosis and severity6,14,15,20 and even the potential
development of liver cancer14 but are also critical modifiers of
disease-associated metabolic traits.6,15 In fact, we previously
demonstrated that epigenetic modifications occurring in the liver
of patients with NAFLD, such as methylation of target sites
(dinucleotides CpG) in the promoter of the peroxisome prolif-
erator-activated receptor gamma coactivator 1a (PPARGC1A, a
master transcription factor involved in liver-related metabolic
pathways, including mitochondrial biogenesis and fatty acid
oxidation, gluconeogenesis, and lipogenesis) adversely affect
peripheral insulin sensitivity.6 Finally, we and others have
previously shown that liver epigenetic changes are not necess-
arily stable but subject to reversion.13,15
The 5-hydroxymethylcytosine (5-hmC) is an old,21 but
recently rediscovered and understood epigenetic modification
that modulates gene transcription by influencing putative DNA
demethylation and chromatin structure remodelling.22 Interest-
ingly, 5-hmC profile seems to be tissue-specific23 and is highly
dependent on the cellular state, resulting in changes in response to
environmental stimuli and metabolic perturbations.24 Non-CG
hydroxymethylation appears to be prevalent in the mitochondrial
genome as well.25,26
The Ten-Eleven-Translocation (TET1, TET2, and TET3)
family of proteins, which share significant sequence homology
at their C-terminal catalytic domains, were recently identified as
5mC hydrolases that catalyze the conversion of 5-mC to
5-hmC.27 These proteins, which frequently mutate in cancer,
are involved in programmed cell death in neurons.28 However,
whether this effect could be observed in hepatocytes
remains unknown.
Because NAFLD is associated with altered DNA methyl-
ation profiles, changes in mtDNA content and PPARGC1A
expression, we hypothesized that epigenetic editing by 5-
hmC might be a novel mechanism through which the
NAFLD-associated molecular traits could be explained. Hence,
we explored the global levels of 5-hmC in the liver of patients
with NAFLD at different stages of disease severity and controls.
In addition, we screened for genetic variation in TET 1–3 loci
by targeted next generation sequencing (NGS) to explore its
contribution to the disease biology.
PATIENTS AND METHODS
Study Design and Patient Selection
This study was conducted in 3 phases: an initial study that
included exploration of global levels of 5-hmC in the liver of
patients with NAFLD (n¼ 67) and control subjects (n¼ 23);
screening of genetic variation of TET1, TET2, and TET3 by
targeted NGS in a discovery group of 96 individuals (64
NAFLD patients and 32 controls); and independent replication
of selected single nucleotide polymorphisms (SNPs) in a case–
control association study (n¼ 380 participants).
Patients were included in the study if there was histopatho-
logical evidence of NAFLD, either NAFL or NASH, based on a
liver biopsy (LB) conducted within the study period. Exclusion
criteria were secondary causes of steatosis, including alcohol
abuse (30 g alcohol daily for men and20 g for women), total
parenteral nutrition, hepatitis B and hepatitis C virus infection,
and the use of drugs known to precipitate steatosis. By using
standard clinical and laboratory evaluation, as well as LB
features when applicable, autoimmune liver disease, metabolic
liver disease, Wilson’s disease, and a-1-antitrypsin deficiency
were likewise ruled out in all patients.
Healthy subjects were selected for inclusion into the
control group if their age and sex matched those of the NAFLD
patients and in whom, in addition to the standard health
assessment described below, a careful ultrasonographic (US)
examination of the liver was performed to exclude fatty liver
infiltration. In addition, controls were included at any study
phase if they did not exhibit features of MetS and did not have
fatty liver at liver US.
For obvious ethical reasons, the control subjects were not
exposed to the potential risk of an LB; hence, in explorations
that involved molecular studies requiring fresh liver tissue,
patients with near-normal liver histology (NNLH) were
included. In the NNLH subjects, LB was justified owing to
the presence of persistently mildly elevated serum activity of
liver enzymes. In all NNLH subjects, all causes of common
liver disease were ruled out, and these patients were included
in the study if they did not present either histological evidence
of fatty change or necrotic-inflammatory activity, and had
either minimal changes or mild cholestasis as histological
diagnosis.
The case participants and the controls were selected during
the same study period from the same population of patients
attending the liver unit, and all shared the same demographic
characteristics.
Ethics, Consent, and Permissions
Human serum and DNA samples from healthy individuals
and those diagnosed with NAFLD, as well as liver biopsies from
all the patients, were obtained with written informed consent
following Institutional Review Board-approved protocols (pro-
tocol number: 104/HGAZ/09, 89/100, and 1204/2012, Comite
de Bioetica Hospital Abel Zubizarreta). All the investigations
performed in this study were conducted in accordance with the
guidelines of the 1975 Declaration of Helsinki.
Physical, Anthropometric, and Biochemical
Evaluation
Health examinations included anthropometric measure-
ments, a questionnaire on health-related behaviors, and
biochemical determinations.
Caspase-generated CK-18 fragment (CK-18)—a noninva-
sive quantification of hepatocellular apoptosis29—concen-
tration was measured by the 1-step in vitro immunoassay
M30-apoptosense enzyme-linked-immunosorbent serologic
assay (ELISA) kit (PEVIVA AB; DiaPharma, OH) that selec-
tively recognizes the caspase-generated fragments of keratin 18
containing the K18Asp396 neoepitope (CK-18).
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Anthropometric measurements and blood samples were
obtained from each patient at the time of LB or DNA sample
collection, and before any intervention. Complete details are
provided in the Supplemental Content, http://links.lww.com/
MD/A400.
Liver Biopsy and Histopathological Evaluation
LB was performed before any intervention with ultrasound
guidance and a modified 1.4 mm-diameter Menghini needle
(Hepafix, Braun, Germany) under local anesthesia, in the out-
patient setting. A portion of each LB specimen was routinely
fixed in 40 g/L formaldehyde (pH 7.4) embedded in paraffin
before being stained with hematoxylin and eosin, Masson
trichrome, and silver impregnation for reticular fibers. All
the biopsies were at least 3 cm in length and contained a
minimum of 8 portal tracts. The liver biopsies were read by
a single experienced hepatopathologist, who was blinded to all
the clinical and laboratory data. The degree of steatosis was
assessed according to the system developed by Kleiner et al.30
NASH was defined as steatosis, accompanied by mixed inflam-
matory-cell infiltration, hepatocyte ballooning and necrosis,
glycogen nuclei, Mallory’s hyaline, and any stage of fibrosis,
including absent fibrosis.31 Complete details are provided in the
Supplemental Content, http://links.lww.com/MD/A400.
Liver Immunohistochemistry
Immunostaining for TET1 protein and 5-hmC was per-
formed on liver specimens previously obtained from NAFLD
patients and controls and included in paraffin before use.
Complete details are provided in the Supplemental Content,
http://links.lww.com/MD/A400.
Electron Microscopy of the Liver Tissue
Electron microscopy (EM) studies were performed on liver
specimens by immersion of a small sample (1 mm) in 2.5%
glutaraldehyde and 0.1 M phosphate buffer (pH 7.4). Sections
were mounted in copper grids, counterstained with lead citrate,
and observed in a transmission electronic microscope (Carl
Zeiss, Carl-Zeiss-Straße 56, 73447 Oberkochen, Germany).
Further details are provided in extant literature.15
RNA Preparation and Real-Time RT-PCR for
Quantitative Assessment of mRNA Expression
and Bisulfite Treatment of DNA for Methylation-
Specific PCR
Total RNA was prepared from liver tissue using phenol
extraction step method, with an additional DNAse digestion.
Genomic DNAwas isolated from liver biopsies at the same time
as RNA by standard methods, and DNA bisulfite modification
was performed as previously reported.6 Complete details are
provided in the Supplemental Content, http://links.lww.com/
MD/A400, which includes details on reverse transcription
polymerase chain reaction (RT-PCR), data normalization, and
the primer sequences.
Global Liver 5-hmC Quantification
We measured global 5-hmC levels in the DNA isolated
from fresh liver specimens of patients and controls using Quest
5-hmC DNA ELISA Kit (Zymo Research, Irvine, CA) accord-
ing to the manufacturer’s instructions. This system is highly
sensitive to 5-hmC DNA and has a detection threshold of 0.02%
per 100 ng input DNA. In brief, 5-hmC was detected using a
sandwich-based ELISA kit that includes a control DNA set,
which was calibrated to accurately quantify the percent 5-hmC
in sample DNA by a standard curve. All samples were measured
in triplicate, allowing us to estimate the mean % 5-hmC level.
The % 5-hmC levels were not normally distributed and were
thus log-transformed for statistical analyses.
Characterization of Genetic Variation in TET 1–3
by NGS
NGS technology was employed to search for the presence
of genetic variation in TET1–3 loci covering all protein-coding
exons (TET1: 9.7 kb, 12 exons, TET2: 19 kb, 13 exons, and
TET3: 11 kb, 9 exons), in addition to exon–intron boundaries
and 50 and 30 UTR regions, which were examined by semi-
conductor technology offered in the Ion Torrent PGM system
(IT-PGM) (Life Technologies, Carlsbad, CA) using a 316 chip.
All reagents were obtained from the same provider. Complete
details are provided in the Supplemental Content, http://
links.lww.com/MD/A400.
Variant Calling, Estimation of Quality Control,
Data Analysis, and Prediction of Variant/
Mutation Effect
Complete details are provided in the Supplemental Con-
tent, http://links.lww.com/MD/A400.
Replication Study: Genotype and Association
Analysis, Power and Sample Size Calculation, and
Population Stratification
The genetic analyses were performed on genomic DNA
extracted from white blood cells. Genotyping of the TET1-
rs3998860 (p.Ile1123Met) and TET2-rs2454206 (p.Ile1762Val)
was performed using a TaqMan genotyping assay (dbSNP
rs3998860 assay C_2719530_10 and dbSNP rs2454206 assay
C_11566753_20; Applied Biosystems, Carlsbad, CA) accord-
ing to the manufacturer’s instructions.
Using the CaTS power calculator for genetic association
studies32 and assuming a prevalence of NAFLD of 0.30, an
minor allele frequency of 0.3, and a relative risk of 2, our
sample had 100% power for the additive genetic model and 98%
for the dominant 1. Complete details are provided in the
Supplemental Content, http://links.lww.com/MD/A400.
Quantification of Liver mtDNA Copy Number
An assay based on real-time quantitative PCR was used for
both nuclear DNA (nDNA) and mtDNA quantification using
SYBR Green as a fluorescent dye (Invitrogen, Carlsbad, CA
92008, USA) as previously described.6 Primer sequences are
shown in Supplemental Content, http://links.lww.com/MD/
A400, along with further details on quantification of liver
mtDNA copy number.
Statistical Analysis
Quantitative data were expressed as mean standard devi-
ation (SD) unless otherwise indicated. Because significant
differences in variance were observed between the groups in
most of the variables and the distribution was significantly
skewed in most cases, we chose to be conservative and assessed
the differences between the groups by using nonparametric
Mann–Whitney U or Kruskal–Wallis tests. As indicated, in
some comparisons, log-transformed variables were compared
by analysis of variance and Neuman–Keuls test for mean
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differences, as in the case of liver 5-hmC levels, liver methyl-
ation and mRNA expression of PPARGC1A, and serum CK-18
levels. Univariate correlations were obtained via the Spearman’s
rank correlation test. For association tests between genotypes or
allele frequencies and phenotypes, such as liver disease and
Type 2 diabetes, Cochran–Armitage test for trend, or logistic
regression were employed.
The CSS/Statistica program package version 6.0 (StatSoft,
Tulsa, OK) was employed in the aforementioned analyses.
RESULTS
Clinical and biochemical features of the entire population
in each of the study phases are shown in Tables 1–3. Overall,
patients with NAFLD had all the features of the MetS, including
abdominal obesity, insulin resistance, hypertriglyceridemia,
and arterial hypertension.
Global Liver DNA Hydroxymethylation Levels
Are Significantly Associated With Liver mtDNA
Content and the Abundance of PPARGC1A-
mRNA
First, we explored the association between liver 5-hmC
levels and NAFLD as a disease trait. The findings revealed no
differences in the overall mean levels of global DNA hydro-
xymethylation in subjects with NNLH (0.100 0.016) and
patients with NAFLD (0.095 0.034), P¼NS. The overall
median (interquartile range, IQR) levels of global DNA hydro-
xymethylation were 0.101% (IQR: 0.035) and 0.094% (IQR:
0.052) for subjects with NNLH and NAFLD, respectively.
The analysis of global liver 5-hmC levels and NAFLD
disease severity did not show significant differences either
(NAFL: 0.090 0.035% vs NASH: 0.100 0.032%, mean,
SD, P¼NS), and the same conclusion was reached for liver
fibrosis (F0–F1: 0.10 0.032% vs F2–F4: 0.094 0.034%,
P¼NS).
To explore the localization pattern of 5-hmC, we further
evaluated the liver specimens (stained by immunohistochem-
istry [IHQ], by a specific antibody) of NAFLD patients and
subjects with NNLH. While the immunoreactivity product of 5-
hmC was preferentially localized in the nucleus of hepatocytes
in both controls and NAFLD patients, with no significant
differences in staining intensity, there were remarkable differ-
ences in both the pattern of nonnuclear localization and the
immunostaining counts. The immunoreactivity product of 5-
hmC in subjects with NNLH was randomly located in non-
nuclear (cytoplasmic) areas of hepatocytes, showing a granular
pattern. Conversely, in patients with NAFLD, 5-hmC was
preferentially localized at the edge of lipid-laden hepatocytes
(Figure 1). Notably, liver specimens of patients with NAFLD
were examined by EM and showed mitochondria in close
physical association with large lipid droplets (Figure 1)—a
finding that supports a putative localization of the nonnuclear
immunoreactivity product of 5-hmC in mtDNA. Further
TABLE 1. Clinical and Biochemical Characteristics of Subjects With Near Normal Liver Histology (NNLH) and Patients With
NAFLD Included in the Exploration of Liver Global Levels of DNA 5-Hydroxymethylation
Variables (Mean SD) NNLH NAFL NASH P Value (P<) P Value (P<) P Value (P<)
Number of subjects 23 31 36 — — —
Age, y 47 9 51 8 48.0 8.7 NS NS NS
BMI, kg/m2 25.5 3.9 31.5 5.0 32.3 6.0 0.00008 0.000032 NS
Waist circumference, cm 91 16 104.0 8.4 107 13 0.027 0.004 NS
Fasting plasma glucose, mg/dL 88.4 11.7 98 13 104 12 0.014 0.000036 NS
Fasting plasma insulin, mU/mL 5.9 1.4 14.5 10.0 15.0 9.5 0.00001 0.000036 NS
HOMA-IR index 1.2 0.3 3.4 2.0 3.9 2.6 0.000005 0.000014 NS
SABP, mm Hg 116 19 124 13 126.0 13.5 0.06 0.04 NS
DABP, mm Hg 72 11 77 13 78.4 8.5 NS NS NS
Total cholesterol, mg/dL 202 41 204 36 218 49 NS NS NS
Triglycerides, mg/dL 145 97 153 68 209 136 NS 0.03 NS
AST, U/L 48.5 37.0 36 16 39 22 NS NS NS
ALT, U/L 74 70 59 39 59 36 NS NS NS
GGT, U/L 110 106 77 83 61 39 0.02 0.01 NS
AP, U/L 259 169 232 123 171 68 NS 0.06 0.04
Histological features
Degree of steatosis, % — 45 27 60.6 21.0 — 0.01
Lobular inflammation (0–3) — 0.5 0.6 0.9 0.6 — — 0.008
Portal inflammation (0–2) — 0 1.5 0.6 — — 0.000001
Hepatocellular ballooning (0–2) — 0 1.00 0.46 — — 0.000001
Fibrosis stage — 0 1.5 0.6 — — 0.000001
NAS — 2.4 1.3 5.8 1.8 — — 0.000001
ALT and AST¼ serum alanine and aspartate aminotransferase, respectively; AP¼ alkaline phosphatase; BMI¼ body mass index; GGT¼ gamma-
glutamyl-transferase; HOMA-IR¼ homeostatic model assessment-insulin resistance; NAFL¼ nonalcoholic fatty liver or simple steatosis;
NAFLD¼ nonalcoholic fatty liver disease; NASH¼ nonalcoholic steatohepatitis; NNLH¼ near-normal liver histology and abnormal liver enzymes;
NS¼ nonsignificant; SABP and DABP¼ systolic and diastolic arterial blood pressure, respectively; SD¼ standard deviation.
NNLH vs NAFL comparisons.
Comparisons between NNLH vs NASH.
Comparisons between NAFL and NASH subjects. The P value pertains to the statistical significance calculated using Mann–Whitney U test.
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analysis on nonnuclear immunostaining scores showed signifi-
cant differences between patients with NAFLD (0.4 0.5) and
controls (1.8 0.8), P¼ 0.028.
We next examined crude linear trends in the association of
global liver DNA hydroxymethylation with continuous pheno-
typic variables, including age, body mass index (BMI), percent
body fat, waist circumference, homeostatic model assessment-
insulin resistance (HOMA-IR), and ALT and AST (serum
alanine and aspartate aminotransferase, respectively) liver
enzyme levels, as well as continuous molecular traits of interest
associated with NAFLD, including expression levels of
PPARGC1A-mRNA and liver mtDNA copy number. Of note,
we found a positive and significant correlation between liver 5-
hmC levels and liver mtDNA content (Spearman R¼ 0.50,
P¼ 0.000382) (Figure 1), and an inverse and significant associ-
ation with the abundance of liver PPARGC1A-mRNA (Spear-
man R¼0.57, P¼ 0.04). As previously reported,6 patients
with NAFLD have a significantly lower liver mtDNA copy
number, expressed as an mtDNA/nDNA ratio (62.5 41.0), in
comparison with subjects with NNLH (103.5 88.0).
In addition, a significant and inverse correlation of liver 5-
hmC levels was found with ALT (Spearman R¼0.24,
P¼ 0.02) and AST (Spearman R¼0.28, P¼ 0.01) serum
levels, and BMI (Spearman R¼0.27, P¼ 0.01).
Analysis of Missense Variation in TET1 and TET2
Loci Shows Association With NAFLD-Disease
Biology and Type 2 Diabetes
TET proteins play a significant role in the generation of
5-hmC; in fact, these enzymes mediate the conversion of 5-mC
to 5-hmC utilizing oxygen and 2-ketoglutarate as substrates.
To understand the potential contribution of genetic vari-
ation in TET1–3 loci in NAFLD-associated molecular traits,
including changes in promoter methylation levels of
PPARGC1a, we followed an NGS approach, which was applied
to all the exons, exon–intron unions and 50 and 30 untranslated
regions of these genes. Furthermore, based on the previous
knowledge of TET-mutations are able to mediate cell death,28
we explored the role of variants on surrogate markers of
hepatocellular apoptosis (release of caspase-cleaved cytoker-
atin-18, CK-18)29 and the disease severity.
In the exploratory study, we generated more than 2 million
reads with an average length of 145 bases of quality equal to or
exceeding Q20, and a coverage on average higher than 100.
Overall, analysis of sequence data yielded 28 SNPs in TET1
gene, 37 in TET2, and 24 in TET3; according to the information
pertaining to the dbSNP or the 1000 genomes, among these, 23
were novel variants.
TABLE 2. Clinical and Biochemical Characteristics of Control Subjects and Patients With NAFLD Included in the Discovery Group
of the Exploration of TET 1–3 Genetic Variation by Next Generation Sequencing
Variables (MeanSD)
Control







Number of subjects 32 32 32 — — —
Age, yr 48.0 7.4 51.9 9.8 51.2 11.0 NS NS NS
BMI, kg/m2 23.0 2.4 31.6 4.7 36.0 5.6 1.0 108 1.0 108 0.003
Waist circumference, cm 80.0 9.1 101.0 8.6 112 14 1.0 108 1.0 108 0.001
Fasting plasma glucose, mg/dL 81.3 7.2 96.5 19.0 127 49 0.0002 1.0 108 0.002
Fasting plasma insulin, mU/mL 5.3 2.4 12.4 6.5 20.9 13.6 1.0 108 1.0 108 0.0007
HOMA-IR index 1.0 0.5 3 2 6.2 4.6 1.0 108 1.0 108 0.0001
SABP, mm Hg 116 9.2 125.0 11.5 133.0 16.4 0.021 0.0008 NS
DABP, mm Hg 72.5 8.6 79 8 79.0 14.6 0.025 0.01 NS
Total cholesterol, mg/dL 219 51 208 59 207 46 NS NS NS
Triglycerides, mg/dL 87 30 149 77 221 142 0.01 0.008 NS
AST, U/L 21.5 4.4 38 19 49.4 33.0 0.001 0.0007 NS
ALT, U/L 21.3 5.0 69 101 60 35 0.001 0.0007 NS
GGT, U/L 36 26 48.0 29.5 86 82 NS 0.039 0.03
AP, U/L 160 67 220 89 269 92 0.04 0.01 0.03
CK18 levels 129 90 243 202 355 284 NS 0.03 NS
Histological features
Degree of steatosis, % — 49 23 60 20 — — 0.05
Lobular inflammation (0–3) — 0.6 0.5 1.4 0.5 — — 0.001
Portal inflammation (0–2) — 0 1.7 0.7 — — 1.0 108
Hepatocellular ballooning (0–2) — 0 0.7 0.6 — — 0.002
Fibrosis stage — 0.1 0.5 1.9 1.2 — — 1.0 108
NAS — 2.4 1.0 6.4 1.6 — — 1.0 108
ALT and AST¼ serum alanine and aspartate aminotransferase, respectively; BMI¼ body mass index; GGT¼ gamma-glutamyl-transferase;
AP¼ alkaline phosphatase; HOMA-IR¼ homeostatic model assessment-insulin resistance; NAFL¼ nonalcoholic fatty liver or simple steatosis;
NAFLD¼ nonalcoholic fatty liver disease; NASH¼ nonalcoholic steatohepatitis; NS¼ nonsignificant; SABP and DABP¼ systolic and diastolic
arterial blood pressure, respectively; SD¼ standard deviation.
NNLH vs NAFL comparisons.
Comparisons between NNLH vs NASH.
Comparisons between NAFL and NASH subjects. The P value pertains to the statistical significance calculated using Mann–Whitney U test.
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Information of genetic variation took precedence over
nonsynonymous SNPs (those that change the amino acid
sequence). Distribution of the variants’ function is depicted
in the Supplemental Content, http://links.lww.com/MD/A400.
As can be seen, a high percentage of genetic variation of TET1
(35.5%) and TET2 (27%) were missense variants. The main
features of variants selected for the replication study, including
chromosome location and predicted functional consequences,
are shown in Supplemental Content, http://links.lww.com/MD/
A400.
The association analysis in the exploratory study showed
that TET1-rs3998860 (p.Ile1123Met) was significantly associ-
ated with serum levels of CK-18 (P¼ 0.003; Figure 2). Repli-
cation analysis performed on the larger validation set confirmed
the initial findings, indicating that hepatocytes of NAFLD
patients who are homozygous for the G allele are more suscept-
ible to apoptosis compared with carriers of the ancestral A allele
(P¼ 0.001). Accordingly, an allelic test showed that the variant
was significantly associated with the disease severity
(Cochran–Armitage test for trend P¼ 0.005); generalized odds
ratio (OR): 1.47, 95% confidence interval (CI): 1.10 to 1.97 for
G vs A allele as a reference. Genotype distribution was in
Hardy–Weinberg equilibrium (P¼ 0.49).
To gain insights into the putative mechanisms by which
this variant might influence the disease phenotype, we next used
IHQ to explore the level of liver TET1 expression according to
rs3998860 genotypes. We observed that TET1 immunoreactiv-
ity product significantly (P¼ 0.036) increased in subjects car-
rying at least 1 copy of the A allele (AA and AG), in comparison
with carriers of the rs3998860-GG genotype (Figure 2).
On the other hand, we aimed to analyze whether genetic
variation in TET1–3 loci plays any role in the modulation of
liver PPARGC1a transcriptional activity. The association
analysis of sequence variation in the exploratory study showed
that p.Ile1762Val substitution (TET2-rs2454206), located in
exon 11, was significantly associated with the liver promoter
methylation status of PPARGC1a (methylated DNA/unmethy-
lated DNA ratio: AA: 0.61 0.1 vs AGþGG: 1.6 0.4,
meanSD, P¼ 0.03 on log transformed values), indicating
that G allele carriers have higher levels of promoter methylation
compared with homozygous AA.
To further assess whether this variant has any effect on
liver gene expression of PPARGC1a, we explored the abun-
dance of the transcript according to the variant genotypes in a
sub-sample of the replication set that had available isolated liver
mRNA (n¼ 66). In line with the findings observed in the
discovery stage, we found that rs2454206 was significantly
associated with the relative abundance of liver PPARGC1a-
mRNA in both the dominant (P¼ 0.005) and additive
(P¼ 0.018) model of inheritance (Figure 3), suggesting that
TABLE 3. Clinical and Biochemical Characteristics of Control Subjects and Patients With NAFLD in the Independent Replication
Study of the Exploration of TET 1–3 Genetic Variation
Variables (Mean SD)
Control







Number of subjects 135 103 142 — — —
Age, yr 48 12 53.6 10.0 51.8 11.0 NS NS NS
BMI, kg/m2 25 4 31.6 5.5 33.0 5.7 1.0 108 1.0 108 0.009
Waist circumference, cm 84 16 103.0 15.4 108 13 1.0 108 1.0 108 0.001
Fasting plasma glucose, mg/dL 81.0 13.6 98 20 130 122 1.0 108 1.0 108 1.0  10–8
Fasting plasma insulin, mU/mL 7.0 4.7 12.9 8.0 16.4 11.0 1.0 108 1.0 108 0.003
HOMA-IR index 1.4 1.0 3.1 2.0 5.3 6.8 1.0 108 1.0 108 0.00008
SABP, mm Hg 115 14 125.4 14.0 128 16 1.0 108 1.0 108 NS
DABP, mm Hg 71.5 9.4 77 11 79 12 1.0 108 1.0 108 NS
Total cholesterol, mg/dL 209 42 205 48 210 43 NS NS NS
Triglycerides, mg/dL 114 79 152 74 192 121 0.0005 1.0 108 0.04
AST, U/L 18.7 24.0 35 17 51 33 0.00001 1.0 108 0.00001
ALT, U/L 17 45 57 63 72 55 0.000001 1.0 108 0.0003
GGT, U/L 24 69 66 58 86 86 0.0002 1.0 108 0.04
AP, U/L 140 118 233 101 227 113 0.000006 0.0001 NS
CK18 levels 136 93 230 231 312 259 NS 0.03 0.04
Histological features
Degree of steatosis, % — 48 26 60 21 — — 0.0003
Lobular inflammation (0–3) — 0.6 0.6 1.2 0.6 — — 1.0 108
Portal inflammation (0–2) — 0 1.50 0.66 — — 1.0 108
Hepatocellular ballooning (0–2) — 0 0.8 0.6 — — 1.0 108
Fibrosis stage — 0 1.5 1.3 — — 1.0 108
NAS — 2.7 1.1 5.9 1.5 — — 1.0 108
ALT and AST¼ serum alanine and aspartate aminotransferase, respectively; AP¼ alkaline phosphatase; BMI¼ body mass index; GGT¼ gamma-
glutamyl-transferase; HOMA-IR¼ homeostatic model assessment-insulin resistance; NAFL¼ nonalcoholic fatty liver or simple steatosis;
NAFLD¼ nonalcoholic fatty liver disease; NASH¼ nonalcoholic steatohepatitis; NS¼ nonsignificant; SABP and DABP¼ systolic and diastolic
arterial blood pressure, respectively; SD¼ standard deviation.
NNLH vs NAFL comparisons.
Stands for comparisons between NNLH vs NASH.
Comparisons between NAFL and NASH subjects. The P value pertains to the statistical significance calculated using Mann–Whitney U test.
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carriers of the G allele have decreased liver expression of
PPARGC1a. Collectively, our findings suggest that the
p.Ile1762Val substitution would be involved in the modulation
of liver PPARGC1a methylation profile, thereby regulating
gene transcription.
To gain insights into possible clinical implications of this
finding, and based on previous knowledge showing that liver
expression of PPARGC1a modulates insulin resistance,6 we
explored the association between the variant and the presence of
Type 2 diabetes in the entire replication set. Notably, we
observed a significant association between the rs2454206 and
Type 2 diabetes, chi-square 10.37, P¼ 0.00128 (OR 1.60 per G
allele, 95% CI: 1.01–2.51; Figure 3). The genotype distribution
was in Hardy–Weinberg equilibrium (P¼ 0.91).
DISCUSSION
Epigenetic modifications, including changes in the DNA
methylation/demethylation rate, are involved in the pathogen-
esis of complex diseases, including NAFLD. It is known that
tissue levels of 5-hmC are variable, and are higher in embryonic
pluripotent stem cells and cells of neuronal lineages, compared
to adult tissue.33–35 In addition, high 5-hmC levels are a feature
of rapidly proliferating cell populations. Nevertheless, 5-hmC
level in the liver of patients with NAFLD presently remains
unknown.
In this study, we aimed to explore global levels of 5-hmC
in the liver of patients with NAFLD at different stages of disease
severity, aiming to better understand its role in the disease
biology. In agreement with a recent study, whereby the authors
measured global 5-hmC levels in nonneoplastic liver tissue of
patients with hepatocelular carcinoma,36 the amount of 5-hmC
in the liver of patients with NAFLD, as well as in the liver of
subjects with NNLH, was relatively low (up to 0.1%). These
findings were confirmed by immunohistostaining of liver sec-
tions with specific anti-5hmC antibody.
Furthermore, while no differences in the global level of
liver 5-hmC between patients and controls were observed, a
significant association was found with molecular traits of
interest, suggesting the possibility of an involvement of hydrox-
ylation of mC in the development of NAFLD. For instance, we
could demonstrate a significant association between liver 5-
hmC and liver mtDNA copy number. Previous work in which
the authors used mtDNA immunoprecipitation by an antibody
directed against 5-hmC supports our findings, showing sub-
stantial 5-hmC levels in the mtDNA.25,26 It is noteworthy to
highlight that a major limitation of all current methodologies
that measure global DNA hydroxymethylation stems from their
FIGURE 1. Global levels of 5-hydroxymethylcytosine (5-hmC) in the liver tissue of patients with NAFLD and near normal liver histology
(NNLH). A: Correlation between log-transformed liver mtDNA/nDNA ratio and log-transformed global liver 5-hmC levels measured by a
sandwich-based enzyme-linked immunosorbent assay employing an anti-5-hydroxymethylcytosine polyclonal antibody. B and C: A
representative specimen of immunostaining for 5-hmC in the liver of a patient with NNLH and NAFLD, respectively. Arrows indicate
nonnuclear areas of 5-hmC staining. D: Magnification shows 5-hmC preferentially localized at the edge of lipid-laden hepatocytes; N ¼
nucleus. Representative electron micrograph of hepatocyte isolated from an NASH patient showing a lipid droplet (LD) and mitochondria
(M) in close physical association with LDs. Magnification:3000. 5-hmC immunoreactivity was examined using light microscopy of liver
sections, while counterstaining was performed with eosin. Original magnification: 400. NAFLD¼nonalcoholic fatty liver disease.
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inability to provide information on whether 5-hmC occurs in the
nuclear or mt genome. Moreover, none provides information
about locus localization in the genome. Nevertheless, we were
able to show that oxidation of mC to hmC is a process that
occurs not only in the nucleus of liver cells but outside them. In
fact, the cytosolic localization of liver 5-hmC by immunostain-
ing strongly suggests mitochondrial localization as extrachro-
mosomal DNA, which is any DNA that is found outside of the
nucleus of a cell, corresponds exclusively to mtDNA. While our
immunohistochemical analysis revealed no differences in the
nuclear 5-hmC staining scores between patients with NAFLD
and controls, we observed that NAFLD was associated with a
significant decrease of nonnuclear 5-hmC suggesting that
mtDNA has different hydroxymethylation levels according to
the disease status.
It is currently unknown whether members of the TET
family are able to target liver mtDNA, as in vitro explorations
in HeLa and 3T3-L1 cells found TET1 and TET2, or only TET1,
respectively, in the mitochondrial fraction, suggesting that the
TET-mtDNA interaction is very much cell-type dependent.26
Thus, we cannot rule out the possibility of an interaction
between 5-hmC and liver mtDNA involving a large regulatory
network, including genes that regulate mitochondrial bio-
genesis, replication and transcription. The significant associ-
ation between liver levels of 5-hmC and liver mtDNA content
allows us to hypothesize that epigenetic editing by hydroxy-
methylation is involved in the regulation of liver mtDNA copy
number. Hydroxymethylated cytosines within the human
mtDNA control region (D-loop), as demonstrated in previous
work,26 strongly support the biological plausibility of our
findings.
In addition, we observed that global 5-hmC levels in the
liver were negatively associated with the abundance of liver
PPARGC1A-mRNA. This finding suggests that the balance
between hypomethylation and hypermethylation in this locus
modulates its transcriptional activity, as we previously reported
by exploring targeted regions of the gene promoter.6 In fact, the
capacity to convert 5-mC into 5-hmC is very much influenced
by the initial amount of 5-mC, which was shown to be higher in
the liver of NAFLD patients.6
On the other hand, we observed that a missense p.Ile1123-
Met variant located in TET methylcytosine dioxygenase 1
(rs3998860) was significantly associated with serum levels of
the CK-18 cell death biomarker. In addition, empirical evidence
indicated that caspase-mediated cleavage of the keratin 18
reflects degradation of the intracellular cytoskeleton when cells
undergo apoptosis.37 This finding was replicated in the vali-
dation sample, in which the rs3998860-G allele was signifi-
cantly associated with the disease severity, suggesting an
involvement of TET1 locus in the modulation of apoptosis
and liver injury in NAFLD. Exploration of a putative functional
role of rs3998860 revealed that immunostaining scores of liver
TET1 were significantly reduced in homozygous carriers of the
G allele. While previous evidence indicated that the effects of
TET1 overexpression on gene transcription are unrelated to its
5-mC dioxygenase function33 TET1-mediated DNA demethy-
lation provides protection against oxidative stress in neuronal
cells.28 In effect, knockdown of tet1 in cerebellar granule cells
FIGURE 2. Association analysis of TET1-rs3998860 (p.Ile1123Met) and serum CK-18 levels. Upper panels: Results of the association
analysis of rs3998860 and serum CK-18 cell death biomarker levels in the discovery and replication stage, left and right, respectively;
caspase-mediated cleavage of the CK-18 reflects degradation of the intracellular cytoskeleton when cells undergo apoptosis. Each bar
represents the mean standard error value. P values pertain to log-transformed serum CK-18 levels, analyzed by analysis of variance.
Lower panels: Representative specimens of immunostaining for liver TET1 protein expression evaluated by immunohistochemistry,
according to TET1-rs3998860 genotypes. Counterstaining was performed using hematoxylin. Original magnification: 400.
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in mice significantly increases apoptosis by promoting neuronal
cell death induced by oxidative stress.28
Finally, we observed that the p.Ile1762Val substitution
(TET2-rs2454206) was significantly associated with liver
PPARGC1A methylation and transcriptional levels. This finding
suggests that the TET2 locus might be involved in the modu-
lation of the liver PPARGC1A methylation/demethylation bal-
ance, putatively in response to the metabolic cellular
environment. More importantly, this molecular trait would
influence the development of Type 2 diabetes, suggesting
new avenues in the understanding of the genetic susceptibility
to diseases that cluster in the metabolic syndrome.
Of note, we were not able to find any significant associ-
ation between global liver 5-hmC levels and genetic variation in
TET-locus; neither we were able to find an association between
TET-variants and mtDNA copy number. Nevertheless, previous
evidence suggest that the dynamics of DNA methylation/
demethylation is governed by a complex interaction of proteins,
including isocitrate dehydrogenases (IDHs) that catalyze the
oxidative decarboxylation of isocitrate to 2-oxoglutarate, which
is a substrate of TET proteins.38 For instance, it was recently
reported that the expression levels of both IDH1 and IDH2
regulate the total 5-hmC content in the adult liver.38 Further-
more, as explained before, it cannot be ascertained whether
mitochondrial 5-hmC is a product of the same enzymatic
reaction that takes place in the nucleus, as there is not
conclusive evidence of the expression of TET proteins in the
mitochondria. Hence, further research is required to guarantee a
deep understanding of the regulatory mechanisms by which 5-
hmC levels are modulated in NAFLD, and so, what are the
mechanisms by which this epigenetic modification regulates
gene expression. Remarkably, IDH-proteins localize to the
mitochondrial matrix and have activity as NADP-dependent
IDH either cytosolic or peroxisomal; the later of particular
significance as NAFLD severity is associated with peroxisome
proliferation.15
In conclusion, our data provide evidence of the involve-
ment of 5-hmC in the modulation of NAFLD phenotype by
regulating liver mitochondrial biogenesis and the transcrip-
tional activity of the co-activator PPARGC1A. In addition,
our findings revealed a putative role of TET1-p.Ile1123Met-
mediated regulation of hepatocyte apoptosis, suggesting the
possibility of an ‘‘epigenetic’’ regulation of programmed liver-
cell death. Using sequencing and replicated data, we also
identified signatures of TET2-p.Ile1762Val-mediated regula-
tion of liver PPARGC1A expression.
Taken together, our findings might contribute as a proof-
of-concept study to the understanding of the role of DNA-
hydroxymethylation and TET proteins in the molecular tissue-
specific quantitative phenotypes associated with NAFLD patho-
genesis and disease severity. To our knowledge, this is the first
report of the influence of liver 5-hmC and TET-mediated
FIGURE 3. Association analysis of TET2-rs2454206 (p.Ile1762Val) and liver methylation and the transcriptional status of the coactivator
PPARGC1A (peroxisome proliferator-activated receptor gamma coactivator 1a). Upper panel: Methylated DNA/unmethylated DNA
ratio for the liver PPARGC1A promoter according to rs2454206 and liver abundance of PPARGC1A mRNA evaluated by quantitative
real-time PCR genotypes in the dominant model of inheritance. Bottom panel: Liver abundance of PPARGC1A mRNA evaluated by
quantitative real-time PCR according to rs2454206 genotypes in the additive model of inheritance, and the distribution of the variant
genotypes according to the presence or absence of Type 2 diabetes in the entire replication set. Each bar represents the mean standard
error value. In each sample, the abundance of target genes was normalized to the amount of cyclophilin to carry out comparisons between
the groups. P values apply to log-transformed values of liver PPARGC1A promoter methylation and mRNA levels. PCR¼polymerase
chain reaction.
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genetic susceptibility of nonmalignant complex diseases. Our
results suggest the importance of early intervention once
NAFLD is suspected/detected, as epigenetic modifications
are potentially reversible and the altered ‘‘liver epigenome’’
can be reversed.13,15 Emerging hypotheses remain to be
explained by the use of novel technologies, including high-
resolution mapping of 5-hmC regions in the mitochondrial
genome and sequencing of additional candidate genes that
regulate the liver methylome.
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Supplemental Figure F1 
 
Figure illustrates genetic variation of TET1 in the whole population explored by next-
generation sequencing: distribution of the predicted function of the variants.  
Information of variants annotation was extracted from dbSNP 
(http://www.ncbi.nlm.nih.gov/SNP/); information on predicted function was based on the 
bioinformatic tool variant Effect Predictor (VEP) 
(http://useast.ensembl.org/Homo_sapiens/Tools/VEP) and SnpEff platform 
(http://snpeff.sourceforge.net/) using University of California, Santa Cruz (UCSC) transcripts  
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Supplemental Figure F2 
 
Figure illustrates genetic variation of TET2 in the whole population explored by next-
generation sequencing: distribution of the predicted function of the variants.  
Information of variants annotation was extracted from dbSNP 
(http://www.ncbi.nlm.nih.gov/SNP/); information on predicted function was based on the 
bioinformatic tool variant Effect Predictor (VEP) 
(http://useast.ensembl.org/Homo_sapiens/Tools/VEP) and SnpEff platform 
(http://snpeff.sourceforge.net/) using University of California, Santa Cruz (UCSC) transcripts  
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Supplemental Figure F3 
 
Figure illustrates genetic variation of TET3 in the whole population explored by next-
generation sequencing: distribution of the predicted function of the variants.  
Information of variants annotation was extracted from dbSNP 
(http://www.ncbi.nlm.nih.gov/SNP/); information on predicted function was based on the 
bioinformatic tool variant Effect Predictor (VEP) 
(http://useast.ensembl.org/Homo_sapiens/Tools/VEP) and SnpEff platform 
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Supplemental Table S1  
Gene Forward primer 5’3’ Reverse primer 5’3’ Size, 
bp 
The primer sequences for mRNA gene expression 
PPARGC1A CCTGCATGAGTCTGTGCTCT GCAAAGAGGCTGGTCTTCAC 164 
PPIA TTCCAGGGTTTATGTGTCA CTCATCTTCAAATTTCTCC 89 
The primer sequences for mtDNA and nDNA amplification 
Mt F3212 CACCCAAGAACAGGGTTTGT TGGCCATGGGTATGTTGTTAA 108 
18S rRNA TAGAGGGACAAGTGGCGTTC3 CGCTGAGCCAGTCA-GTGT 105 












Table that illustrates PCR primers used for exploration of liver PPARGC1A mRNA abundance and 
promoter mthylation status, and liver mtDNA copy number 
 
PPARGC1A=peroxisome proliferator-activated receptor gamma, coactivator 1 alpha; 




Epigenetic Modifications in the Biology of Nonalcoholic Fatty Liver Disease: The Role of 
DNA-Hydroxymethylation and TET Proteins  
 
Authors: Carlos J Pirola PhD, Romina Scian PhD, Tomas Fernández Gianotti PhD, Hernán 




















Isoleucine (I) to 
Methionine (M) 
at position 1123  









Isoleucine (I) to 
Valine (V) at 
position 1762 






Table that illustrates the main features of variants identified in TET locus by next 
generation sequencing and selected for following up in the replication study  
 
* MAF indicates minor allele frequency in the 1000 Genome Project.  
TET1: Ten-Eleven Translocation-1 or tet methylcytosine dioxygenase 1, TET2: Ten-Eleven 
Translocation-2 or tet methylcytosine dioxygenase 2.  
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1a-Physical, anthropometric, and biochemical evaluation 
1b. Liver biopsy and histopathological evaluation 
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1a. Physical, anthropometric, and biochemical evaluation 
The body mass index (BMI) was calculated as weight/squared height (kg/m
2
) and was used as an 
index for relative weight. The waist and hip circumferences were also measured. Elevated blood 
pressure was defined as systolic arterial blood pressure (SABP)  130 mm Hg and/or diastolic 
(DABP)  85 mm Hg, or evidence of antihypertensive treatment.  
Biochemical determinations: Blood was drawn from 12-hour fasting subjects that had been in a 
supine resting position for at least 30 min. Laboratory evaluation included serum ALT and AST, 
gamma glutamyl transferase (γGT), alkaline phosphatase (AP), glucose and insulin, total 
cholesterol and plasma triglycerides (TG). All biochemical determinations were measured using 
a Hitachi-912 Autoanalyzer (Roche, Diagnostic, Buenos Aires, Argentina) or Immulite 1000 
(DPC, Buenos Aires, Argentina). Homeostasis Model Assessment (HOMA-IR) was used to 
evaluate an insulin resistance index and was calculated as follows: Fasting serum insulin (U/ml) 
× Fasting plasma glucose (mmol/l) / 22.5.  
 
1b. Liver biopsy and histopathological evaluation 
The degree of steatosis was assessed according to the system developed by Kleiner et al. 
1
 based 
on the percentage of hepatocytes containing macrovesicular fat droplets: grade 0 = <5%; grade 1 
= 5-33%; grade 2 = 34% to 66% and grade 3 = >66%. NASH was defined as steatosis, 
accompanied by mixed inflammatory-cell infiltration, hepatocyte ballooning and necrosis, 
glycogen nuclei, Mallory’s hyaline, and any stage of fibrosis, including absent fibrosis 
2
. Intra-
acinar (lobular) inflammation was defined according to Brunt 
2
 as presence of cellular 
components of inflammation (polymorphonuclear leukocytes, lymphocytes and other 
mononuclear cells, eosinophils and microgranulomas) located in sinusoidal spaces, surrounding 
Mallory’s hyaline or in hepatocellular necrosis. It was graded 0–3 and was defined as 0 (absent) 
= no foci; 1 = < 2 foci per 200 × field; 2 = 2 to 4 foci per 200 × field; and 3 = >4 foci per 200 × 
field. Ballooning was scored as: 0 = none; 1 = rare or few; and 2 = many. The severity of fibrosis 
was expressed on a 4-point scale, as follows: 0 = none; 1 =perivenular and/or perisinusoidal 




Four-micrometer sections were mounted onto silane-coated glass slides to ensure section 
adhesion through subsequent staining procedures. Briefly, sections were deparaffinized, 
rehydrated, and washed in phosphate buffer solution (PBS), before being treated with 3% H2O2 
in PBS for 20 min at room temperature to block endogenous peroxidase. Following microwave 
heat-induced epitope retrieval in 0.1 M citrate buffer at pH 6.0 for 20 min, the slides were 
incubated with a dilution of 1:100 of TET1 (PAB21054, Abnova Taipei, Taiwan) and 1:500 of 5-
hmc (Active Motif 39770, CA, USA). Immunostaining was performed using the VECTASTAIN 
Elite ABC Kit (Vector Lab. CA, USA) detection system. Subsequently, slides were immersed in 
a 0.05% 3,3'-diaminobenzidine solution in 0.1 M Tris buffer, pH 7.2, containing 0.01% H2O2. 
After brown color developed, slides were removed and the reaction was arrested by immersion in 
PBS. Hematoxylin was used as a counterstain for TET1 and eosin for 5-hmc. Immunostaining 
was semi-quantitatively evaluated in a blinded fashion regarding any of the histological and 
clinical characteristics of the patients by two independent observers. The extent of staining was 
scored according to its amount and intensity, using a 4-point scoring system, as follows: 0 = no 
staining; 1 = positive staining in less than 20% of cells; 2 = 21-50% of positive cells, and 3 = 
positive staining in more than 50% of cells. Scoring included nuclear and cytoplasm staining and 
the sections were observed by bright field microscopy, using an Axiostar plus (Carl Zeiss, 
Germany) microscope at a 400× magnification.  
 
1d-RNA preparation and real-time RT-PCR for quantitative assessment of mRNA expression 
For RT-PCR, 1 to 3 g of total RNA was reverse-transcribed using random hexamers and 
Moloney Murine Leukemia Virus (MMLV) reverse transcriptase (Promega, Wisconsin, USA). 
Real-time PCR was performed for quantitative assessment of mRNA expression in a StepOne 
Plus Real-Time PCR Systems (Applied Biosystems, CA 94404, USA). All the real-time PCR 
reactions were run in triplicate. The mRNA abundance of target genes was normalized to the 
amount of a housekeeping gene (cyclophilin A) to carry out comparisons between the groups. 
The selection of the housekeeping gene was based on the exploration of the most stable reference 
gene for testing liver mRNA expression among other housekeeping genes (-actin, TATA box 
binding protein, cyclophilin A and glyceraldehyde-3-phosphate dehydrogenase) tested before 
starting this experiment. The geNorm program 
3
 was used to identify the appropriate reference 
control in our samples. The mRNA levels were expressed as the ratio of the estimated amount of 
the target gene relative to the cyclophilin A mRNA levels using fluorescence threshold cycle 
values (Ct) calculated for each sample, and the estimated efficiency of the PCR for each product 
was expressed as the average of all sample efficiency values obtained 
4
. The specificity of 
amplification and absence of primer dimers were confirmed using the melting curve analysis at 
the end of each run.  
 
1e-Bisulfite treatment of DNA and methylation-specific polymerase chain reaction 
DNA bisulfite modification was based on bisulfite treatment of genomic DNA, thereby 
converting all the unmethylated cytosines to uracils, while conserving the methylated cytosines, 
by the EZ DNA Methylation Kit, according to the manufacturer’s protocol (Zymo Research 
Corporation, Orange, CA, USA). The chemically modified DNA was subsequently used as a 
template for a methylation-specific polymerase chain reaction (MS-PCR) to determine the 
promoter methylation status of the selected CpG dinucleotides in the PPARGC1A promoter. The 
assay was based on a real-time quantitative PCR in an iCycler thermocycler (BioRad Hercules, 
CA, USA) using SYBR Green (Invitrogen, Buenos Aires, Argentina) as a fluorescent dye. 
For the MS-PCR experiment, two pairs of primers were used: one pair was specific for bisulfite-
modified methylated DNA (M primers) and the other pair was specific for bisulfite-modified 
unmethylated DNA (U primers). Thus, for each sample studied, two PCRs were performed 
simultaneously using the M primer and U primer pairs. Successful amplification from the M 
primers and U primers indicated methylation and unmethylation, respectively. For primer design, 
a sequence starting 2000 bp upstream from the transcriptional start site (TSS) of PPARGC1A 
was used in the MethPrimer program (http://www.urogene.org//methprimer/index1.html) to 
search for regions with potentially methylated CpG sites. For maximal discrimination between 
methylated and unmethylated alleles, M and U primers were designed to contain at least one 
CpG site at the 3'.  
The level of methylated DNA is expressed as the ratio of the estimated amount for methylated 
DNA to the unmethylated DNA levels, calculated for each sample using the fluorescence 
threshold cycle (Ct) values for a previously estimated efficiency, according to a previous report 
5
. 
We estimated the efficiency for each single sample tube using the slope of the exponential phase, 
as described by Ramakers et al. 
6
. Furthermore, as expected, controls for unmethylated (a 
purified native amplicon) and fully methylated DNA (the same amplicon treated with the DNA 
methylase M.SssI (New England Biolabs, Ipswich, MA, USA) gave 0 and 100% DNA 
methylation patterns.  
All the experiments were carried out in triplicate. The CV% was observed to be less than 5%. 
The specificity of amplification and the absence of primer dimers were confirmed by melting 
curve analysis at the end of each run and agarose electrophoresis. 
To ensure the specificity of the method and to avoid variability in the results because of the 
presence of two CpG dinucleotides in the reverse primer, we designed a degenerated reverse 
primer that introduced a mismatch in the second CG site, and observed the absence of 
amplification, regardless of the target DNA (data not shown), indicating that primers recognize 
the status of both the CpG dinucleotides simultaneously. 
 
1f-Quantification of mtDNA 
An assay based on real-time quantitative PCR was used for both nuclear DNA (nDNA) and 
mitochondrial DNA (mtDNA) quantification using SYBR Green as a fluorescent dye 
(Invitrogen) as previously described 
7
. Results were presented as the mtDNA/nDNA ratio. 
Real-time quantitative PCR was carried out in a
 
BioRad iCycler (Bio-Rad). The calculation of 
DNA copy number involved extrapolation from the fluorescence readings in the mode of 
background subtracted from the BioRad iCycler according to Rutledge et al.
8
. Specificity of 
amplification and the absence of primer dimers were confirmed by the melting curve analysis at 
the end of each run. The two target amplicon sequences (mtDNA and nDNA) were visualized in 
agarose 2% and purified by Qiagen Qiaex II, Gel extraction Kit (Tecnolab, Buenos Aires, 
Argentina), and dilutions of purified amplicons were used as the standard curve. The inter-assay 






1g-Next generation sequencing (NGS)  
DNA was isolated from whole blood, as previously described 
10
 and was quantified by a Qubit 
DNA high-sensitivity assay kit.  
Library preparation for each sample was performed using the IT AmpliSeq 2.0 Beta kit 
following the manufacturer's instructions. Briefly, 10 ng of DNA was used as a template to 
generate the amplicon library for sequencing variation in the three genes. Genomic regions of 
interest were PCR amplified prior to sequencing, and the sequencing adaptors with short 
stretches of index sequences (96 barcodes) that enabled sample identification were ligated to the 
amplicons using the IT Xpress barcode adaptor kit. The prepared library was quantified using the 
Ion library TaqMan Quantitation Kit. Sequencing template preparation (emulsion PCR and 
beads-enrichment) from sequencing libraries was carried out using an Ion OneTouch Template 
Kit and Ion OneTouch system (Ion OneTouch Instrument and Ion OneTouch ES, Life 
Technologies, Carlsbad, CA, USA) according to the manufacturer’s protocol. Prepared templates 
were sequenced using Ion Sequencing Kit v2. Ion Torrent Suite software 4.2.1 (Life 
Technologies, Carlsbad, CA, USA) was used for converting raw signals into base calls and 
extracting FASTQ files of sequencing reads. Number of nucleotide flows during sequencing was 
set to 500 cycles. 
1h-Variant calling, estimation of quality control, data analysis and prediction of variant/ 
mutation effect 
The data obtained from the Ion Torrent PGM were processed using the Ion Torrent Suite 
Software v 4.2.1 (Life Technologies, Carlsbad, CA, USA). Variants were annotated with dbSNP 
(http://www.ncbi.nlm.nih.gov/SNP/) IDs using SnpSift. In silico analysis, aimed at predicting 
gene and transcript functional consequences was performed by the bioinformatic tool variant 
Effect Predictor (VEP) (http://useast.ensembl.org/Homo_sapiens/Tools/VEP), employing 
ENSEMBL transcripts and SnpEff platform (http://snpeff.sourceforge.net/) using University of 
California, Santa Cruz (UCSC) transcripts. CellBase 
11
 available at 
http://docs.bioinfo.cipf.es/projects/cellbase was used to annotate variants with the phenotype 
information from HGMD, ClinVar, UNIPROT and COSMIC. Annotation in 
http://www.ncbi.nlm.nih.gov/SNP was also used to determine whether variants were novel or 
already associated with a phenotype. 
Read alignment to the hg19 Human genome reference sequence was performed using torrent 
mapping alignment program (TMAP) included in PGM. The Ion Torrent variant caller plug-in 
was used to perform the variant calling with the germline low stringency settings. In order to 
filter erroneous base callings, control quality filtering steps were performed using proprietary 
Perl scripts. At the variant coverage depth > 20, we inspected the presence of strand bias by 
checking the number of bases covered in both strands for the variant, the reference =/ > 4 reads 
in both strands, and the quality for variant calling > 20. The retained variants were visually 
examined using Integrative Genomics Viewer (IGV) software 
(http://www.broadinstitute.org/igv/) to check for any inconsistency in the base calls. 
 
1i-Replication study: Genotype and association analysis, power and sample size calculation, 
and population stratification 
To ensure genotyping quality, we included DNA samples as internal controls, hidden samples of 
known genotype, and negative controls (water). The overall genotype completion rate was 100%. 
To account for possible population stratification, we used a collection of 13 SNPs (rs6830727, 
rs12639788, rs1282807, rs1947745, rs7162312, rs12951674, rs7212346, rs1934869, rs9542666, 
rs11843545, rs9725124, rs2798659, and rs2199940) at different loci (located in chromosomes 4, 
15, 17, 13, 1, and 3) and then analyzed the data with the Structure program Version 2 
12
.  
We found no evidence of stratification in our sample because Q values were similar for the cases 
and the controls. Moreover, the Structure program assigned a similar distance to clusters and no 
further improvement in the fitting model was achieved by adding up to four clusters (the ln of 
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